Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients

PurposeTo determine the safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution (Vigamox) in patients having cataract surgery.SettingAmerican Eye Center, Manila, Philippines.MethodsPreoperative and 1-month postoperative anterior chamber reaction, corneal endothelial cell density, and corneal thickness were assessed in 65 eyes that had cataract surgery with intracameral moxifloxacin. All eyes received 0.1 mL intracameral moxifloxacin 0.5% ophthalmic solution containing 500 μg of moxifloxacin as the last step of phacoemulsification. Different ophthalmologists conducted the postoperative evaluation in an observer-masked fashion. A P value less than 0.05 was considered significant.ResultsAll 65 eyes completed the study. The mean age was 69.5 years ± 9.13 (SD) (range 48 to 84 years). All eyes had a postoperative best corrected visual acuity of 20/30 or better. All eyes had trace to +2 cells and flare anterior chamber reaction only on the first day after surgery. The mean endothelial cell count was 2491.52 cells/mm2 preoperatively and 2421.58 cells/mm2 postoperatively. The mean difference was 70 cells/mm2, which not statistically significant (P = .737). The increase of 17.80 μm in postoperative pachymetry 1 month after surgery was not statistically significant (P>.65).ConclusionIntracameral Vigamox 0.5 mg/mL appeared to be nontoxic in terms of visual rehabilitation, anterior chamber reaction, pachymetry, and corneal endothelial cell density.